Communications with Health Canada

One of the members of PSSD Canada has been dedicated to the goal of accessing information on the post-market review of antidepressants for long-term sexual dysfunction that Health Canada has been engaged in since 2018.

We recently received this message from the Marketed Health Products Directorate at Health Canada:

“Thank you for your email dated Dec. 1st, 2020.

This is in response to your email in which you requested to know when the final review for Post SSRI Sexual Dysfunction (PSSD) will be concluded.

Health Canada, as part of it’s safety assessment, must review various types of information (including but not limited to information from peer review journals, other regulatory agencies and adverse reaction reports). Additionally, with regards to the review for Post SSRI Sexual Dysfunction (PSSD), several consultations were also undertaken involving different stakeholders which has contributed to some additional review time.

We expect that the conclusions and results for the review of PSSD will be available at the beginning of 2021.

Again, thank you for waiting. We hope this information is helpful to you. “

We will continue to post updates as they develop.